(a) Prosecution for any violation of law occurring prior to the effective date of this chapter is not affected or abated by
this chapter. If the offense being prosecuted is similar to one set out in subchapter IV of this chapter, then the penalties
under subchapter IV apply if they are less than those under prior law.
(b) Civil seizures or forfeitures and injunctive proceedings commenced prior to the effective date of this chapter are not
affected by this chapter.
(c) All administrative proceedings pending under prior laws which are superseded by this chapter shall be continued and brought
to a final determination in accord with the laws or rules in effect prior to the effective date of the chapter. Any substance
controlled under prior law which is not listed within Schedules I through V is automatically controlled without further proceedings
and shall be listed in the appropriate schedule.
(d) The Secretary shall initially permit persons to register who own or operate any establishment engaged in the manufacture,
distribution or dispensing of any controlled substance prior to the effective date of this chapter and who are registered
or licensed by the State.
(e) This chapter applies to violations of law, seizures and forfeiture, injunctive proceedings, administrative proceedings
and investigations which occur following its effective date.
16 Del. C. 1953, § 4773; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4792. Continuation of rules.
Any orders and rules promulgated under any law affected by this chapter and in effect on the effective date of this chapter
and not in conflict with it continue in effect until modified, superseded or repealed.
16 Del. C. 1953, § 4774; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4793. Uniformity of interpretation.
This chapter shall be so applied and construed as to effectuate its general purpose to make uniform the law with respect to
the subject of this chapter among those states which enact it.
16 Del. C. 1953, § 4775; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4794. Short title.
This chapter may be cited as the Uniform Controlled Substances Act.
16 Del. C. 1953, § 4776; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4795. Jurisdiction.
(a) The Superior Court shall have original and exclusive jurisdiction over any violation of this chapter by persons 18 years
of age or older.
(b) The provisions of subsection (a) of this section or any other law to the contrary notwithstanding, the Court of Common
Pleas shall have original jurisdiction over any violation of:
(1) Section 4754(b) of this title;
(2) Section 4757(c) of this title; and
(3) Section 4771 of this title,
by persons 18 years of age or older, except that the Municipal Court of the City of Wilmington shall have original jurisdiction
concurrent with the Court of Common Pleas for such violations by persons 18 years of age or older occurring within the City
of Wilmington.
(c) The Family Court shall have original and exclusive jurisdiction over violations of this chapter by persons under age 18.
16 Del. C. 1953, § 4777; 58 Del. Laws, c. 424, § 1; 58 Del. Laws, c. 480, § 3; 61 Del. Laws, c. 261, § 4; 62 Del. Laws, c. 250, § 5; 71 Del. Laws, c. 63, §§ 2, 3; 71 Del. Laws, c. 176, § 25.;
§ 4796. Authority of the Attorney General.
Nothing in this chapter shall be interpreted as limiting the authority or responsibility of the Attorney General of this State
to enforce the laws of this State.
16 Del. C. 1953, § 4778; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
(a) Effective October 1, 2010, every prescription written in this State by a practitioner shall be written on a statewide
authorized tamper-resistant prescription form. This section shall not apply to prescriptions generated within a licensed medical
facility that results in the internal dispensing of prescription drugs to any patient receiving treatment in that facility,
nor to tamper-resistant prescription forms electronically generated within a licensed medical facility that meet the criteria
established by the committee created under this section.
(b) "Statewide tamper-resistant prescription pads" shall be defined as a prescription pad, which has been authorized by the
State for use, and meets the following criteria:
(1) Prevention of unauthorized copying,
(2) Prevention of erasure or modification; and
(3) An ability to prevent counterfeit prescription forms.
(c) The Secretary of the Delaware Department of Safety and Homeland Security (DSHS), or the Secretary's designee, shall form
a committee consisting of representatives of state agencies and private sector interests. The purpose of the committee is
to establish a statewide prescription form with specific criteria pursuant to this section to eliminate or significantly reduce
prescription fraud. The committee shall develop the standard format and identifying markers on the front and back of the prescription
form to be used by practitioners throughout the State. "Markers" shall be defined as the specific criteria under this subsection
which shall be authorized by the State to be used on a statewide prescription form. The committee shall further develop a
request for proposal which shall contain the adopted format and criteria approved by the committee to be submitted for bid
to the State. The committee shall also have the authority to promulgate rules and regulations for the implementation of the
provisions of this subsection. The committee shall be comprised of the following members:
(1) The Secretary of the Department of Safety and Homeland Security or the Secretary's designee;
(2) A representative from the Office of Narcotics and Dangerous Drugs to be appointed by the Secretary of the Department of
Safety and Homeland Security;
(3) A representative from the Medical Society of Delaware to be appointed by the Governor;
(4) A representative from the pharmaceutical industry to be appointed by the Governor;
(5) The Director of the Division of Professional Regulation or the Director's designee;
(6) A representative of the Delaware Healthcare Facilities Association to be appointed by the Governor;
(7) The Director of Medicaid and Medical Assistance or the Director's designee;
(8) A representative of the Board of Pharmacy to be appointed by the Director of the Division of Professional Regulation;
(9) A representative from the Delaware Healthcare Association to be appointed by the Governor;
(10) A representative from the Office of Controlled Substances to be appointed by the Director of the Division of Professional
Regulation;
(11) A representative from the Delaware Pharmacists Society to be appointed by the Governor;
(12) Two members at-large to be appointed by the Governor of the State.
76 Del. Laws, c. 352, § 1; 70 Del. Laws, c. 186, § 1; 77 Del. Laws, c. 159, § 1.;
§ 4798. The Delaware Prescription Monitoring Program [Effective upon provision of funding; see 77 Del. Laws, c. 396, § 3]
(a) It is the intent of the General Assembly that the Delaware Prescription Monitoring Act established pursuant to this section
serves as a means to promote public health and welfare and to detect the illegal use of controlled substances. The Delaware
Prescription Monitoring Act shall have the dual purpose of reducing misuse and diversion of controlled substances in the State
while promoting improved professional practice and patient care.
(b) Definitions. --
(1) "Administer" or "administration" means the direct application of a drug to the body of a patient by injection, inhalation,
ingestion, or any other means.
(2) "Controlled substance" means any substance or drug defined, enumerated or included in this chapter and Title 21, Code
of Federal Regulations.
(3) "Dispense" or "dispensing" means the interpretation, evaluation, and implementation of a prescription drug or, including
the preparation and delivery of a drug to a patient or patient's agent in a suitable container appropriately labeled for subsequent
administration to, or use by, a patient.
(4) "Dispenser" means a person authorized by this State to dispense or distribute to the ultimate user any controlled substance
or drug monitored by the program, but shall not include any of the following: a licensed health care facility pharmacy that
dispenses or distributes any controlled substance or drug monitored by the program for the purposes of inpatient care, emergency
department care for the immediate use of a controlled substance or when dispensing up to a 72-hour supply of a controlled
substance or a drug of concern monitored by the program at the time of discharge from such a facility.
(5) "Distribute" or "distribution" means the delivery of a drug other than by administering or dispensing.
(6) "Drug" means any of the following:
a. Any substance recognized as a drug in the official compendium, or supplement thereto, designated by the Office of Controlled
Substances for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans.
b. Any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or pain in humans.
c. Any substance other than food intended to affect the structure or any function of the body of humans.
(7) "Drugs of concern" means drugs other than controlled substances as defined by rule which demonstrate a potential for abuse
or diversion.
(8) "Patient" means the person who is the ultimate user of a controlled substance or drug monitored by the program for whom
a prescription is issued and for whom a controlled substance or drug is dispensed.
(9) "Prescriber" means a licensed health care professional with the authority to write and issue prescriptions, except it
shall not include:
a. A prescriber or other authorized person who administers such controlled substance or drug upon the lawful order of a prescriber.
b. A prescriber or other authorized person who, in providing emergency patient care in a healthcare facility, causes the administration
of a controlled substance for immediate relief of symptoms arising from an acute condition.
c. A prescriber or other authorized person who prescribes up to a 72-hour supply of a controlled substance for on call services
or emergency care.
d. A veterinarian who prescribes for the purpose of providing veterinary services.
(10) "Prescription monitoring information" means data submitted to and maintained by the prescription monitoring program established
under this section.
(11) "Prescription Monitoring Program" or "PMP" means the electronic program established by this section.
(c) The Office of Controlled Substances shall establish and maintain a PMP program to monitor the prescribing and dispensing
of all Schedule II, III, IV and V controlled substances by prescribers in this State, and to research the prescribing and
dispensing of drugs of concern. The PMP shall not interfere with the legal use of a controlled substance or drug of concern.
The PMP shall be:
(1) Used to provide information to prescribers, dispensers, and patients to help avoid the illegal use of controlled substances;
(2) Used to assist law enforcement to investigate illegal activity related to the prescribing, dispensing and consumption
of controlled substances or drugs of concern; and
(3) Designed to minimize inconvenience to patients and prescribing medical practitioners while effectuating the collection
and storage of prescription monitoring information.
(d) A dispenser shall submit the required information regarding each prescription dispensed for a controlled substance, in
accordance with the transmission methods and frequency established by regulation issued by the Office of Controlled Substances.
When needed for bona fide research purposes and in accordance with applicable regulation, the Office of Controlled Substances
may require a dispenser to submit the required information regarding each prescription dispensed for a drug of concern, but
in no event should dispensers be required to submit such information any more frequently than that required for controlled
substances. The following information shall be submitted for each prescription:
(1) Pharmacy name;
(2) Dispenser DEA registration number;
(3) Date drug was dispensed;
(4) Prescription number;
(5) Whether prescription is new or a refill;
(6) NDC code for drug dispensed;
(7) Quantity dispensed;
(8) Approximate number of days supplied;
(9) Patient name and date of birth;
(10) Patient address;
(11) Prescriber DEA registration number and name;
(12) Date prescription issued by prescriber.
(e) A prescriber, or other person authorized by the prescriber, shall obtain, before writing a prescription for a controlled
substance listed in Schedule II, III, IV or V for a patient, a patient utilization report regarding the patient for the preceding
12 months from the computerized program established by the Office of Controlled Substances when the prescriber has a reasonable
belief that the patient may be seeking the controlled substance, in whole or in part, for any reason other than the treatment
of an existing medical condition. The prescriber shall review the patient utilization report to assess whether the prescription
for the controlled substance is necessary.
(f) The Office of Controlled Substances may issue a waiver to a prescriber who is unable to access prescription information
by electronic means. A prescriber who is unable to access prescription information by electronic means shall obtain a waiver
from the OCS on annual basis until such time they can access the prescription information by electronic means.
(g) Unless a court of competent jurisdiction makes a finding of gross negligence, malice or criminal intent, the Office of
Controlled Substances, any other state agency, any prescriber or dispenser, or any person or entity in proper possession of
information pursuant to this statute is not subject to civil liability, administrative action or other legal or equitable
relief for any of the following acts or omissions:
(1) Furnishing information pursuant to this section.
(2) Receiving, using or relying on, or not using or relying on, information received pursuant to this section.
(3) Information that was not furnished to the Office of Controlled Substances.
(4) Information that was factually incorrect or that was released by the Office of Controlled Substance to the wrong person
or entity.
(h) Prescription information submitted to the PMP is protected health information, not subject to public or open records law,
and not subject to disclosure, except as otherwise provided in this section.
(i) The Office of Controlled Substances shall maintain procedures to ensure that the privacy and confidentiality of patients
and patient information collected, recorded, transmitted, and maintained is not disclosed, except as provided for in this
section.
(1) If there is reasonable cause to believe a violation of law or breach of professional standards may have occurred, the
Office of Controlled Substances shall notify the appropriate law-enforcement or professional licensure, certification, or
regulatory agency or entity and shall provide prescription information required for an investigation.
(2) The Office of Controlled Substances may provide data in the prescription monitoring program in the form of a report to
the following persons:
a. A prescriber, or other person authorized by the prescriber, or a dispenser, or other person authorized by the dispenser,
who requests information and certifies that the requested information is for the purpose of providing medical or pharmaceutical
treatment to a bona fide patient;
b. An individual who requests the individual's own prescription monitoring information in accordance with procedures established
pursuant to regulations;
c. A designated representative of any Board or Commission pursuant to § 8735(a) of Title 29 responsible for the licensure,
regulation, or discipline of prescribers, dispensers or other persons authorized to prescribe, administer, or dispense controlled
substances and who is involved in a bona fide specific investigation involving a designated person;
d. A local, state, or federal law-enforcement or prosecutorial official engaged in the administration, investigation, or enforcement
of the laws governing controlled substances and who is involved in a bona fide specific drug-related investigation in which
a report of suspected criminal activity involving controlled substances by an identified suspect has been made, and provided
that such information be relevant and material to such investigation, limited in scope to the extent reasonably practicable
in light of the purpose for which the information is sought, and include identifying information only if nonidentifying information
could not be used;
e. The Delaware Department of Health and Social Services regarding Medicaid program recipients;
f. A properly convened grand jury pursuant to a subpoena properly issued for the records;
g. Personnel of the Division of Professional Regulation for purposes of administration and enforcement of this section;
h. Qualified personnel for the purpose of bona fide research or education; however, data elements that would reasonably identify
a specific recipient, prescriber or dispenser must be deleted or redacted from such information prior to disclosure; and further
provided that, release of the information may be made only pursuant to a written agreement between qualified personnel and
the Office of Controlled Substances in order to ensure compliance with this subsection.
(j) The Division of Professional Regulation may contract with another agency of this State or with a private vendor, as necessary,
to ensure the effective operation of the prescription monitoring program. A contractor shall comply with the provisions regarding
confidentiality of prescription information under this section is subject to the penalties specified in this section for any
unlawful acts.
(k) The Office of Controlled Substances may promulgate regulations setting forth the procedures and methods for implementing
this section.
(l) The Office of Controlled Substances shall design and implement an evaluation component to identify cost-benefits of the
Prescription Monitoring Program, including its effect on diversion and abuse of controlled substances and drugs of concern,
and other information relevant to policy, research and education involving controlled substances and drugs of concern monitored
by the Prescription Monitoring Program.
(1) The Office of Controlled Substances shall report to the General Assembly the information obtained pursuant to this subsection
on an annual basis.
(2) To the extent such information is made available to the Office of Controlled Substances, the report may include information
and data, including surveys, polls, or other data from multi-disciplinary experts and stakeholders, relating to the negative
or positive impact of the prescription monitoring program on appropriate prescribing practices of controlled substances and
drugs of concern.
(m) A dispenser who fails to submit prescription monitoring information to the Office of Controlled Substances PMP as required
by this section, or who knowingly submits incorrect prescription information, shall be subject to disciplinary sanction pursuant
to Chapter 25 of Title 24.
(n) A person or persons authorized to have prescription monitoring information pursuant to this section who knowingly discloses
this information in violation of this section is guilty of a class G felony and, upon conviction, shall be fined not more
than $5,000 nor imprisoned more than 2 years, or both.
(o) A person authorized to have prescription monitoring information pursuant to this section who intentionally uses this information
in the furtherance of other crimes is guilty of a class E felony and, upon conviction, shall be fined not more than $10,000
nor imprisoned more than 5 years, or both.
(p) A person or persons not authorized to have prescription monitoring information pursuant to this section who obtain such
information fraudulently is guilty of a class E felony and, upon conviction, shall be fined not more than $10,000 nor imprisoned
more than 5 years, or both.
(a) Prosecution for any violation of law occurring prior to the effective date of this chapter is not affected or abated by
this chapter. If the offense being prosecuted is similar to one set out in subchapter IV of this chapter, then the penalties
under subchapter IV apply if they are less than those under prior law.
(b) Civil seizures or forfeitures and injunctive proceedings commenced prior to the effective date of this chapter are not
affected by this chapter.
(c) All administrative proceedings pending under prior laws which are superseded by this chapter shall be continued and brought
to a final determination in accord with the laws or rules in effect prior to the effective date of the chapter. Any substance
controlled under prior law which is not listed within Schedules I through V is automatically controlled without further proceedings
and shall be listed in the appropriate schedule.
(d) The Secretary shall initially permit persons to register who own or operate any establishment engaged in the manufacture,
distribution or dispensing of any controlled substance prior to the effective date of this chapter and who are registered
or licensed by the State.
(e) This chapter applies to violations of law, seizures and forfeiture, injunctive proceedings, administrative proceedings
and investigations which occur following its effective date.
16 Del. C. 1953, § 4773; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4792. Continuation of rules.
Any orders and rules promulgated under any law affected by this chapter and in effect on the effective date of this chapter
and not in conflict with it continue in effect until modified, superseded or repealed.
16 Del. C. 1953, § 4774; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4793. Uniformity of interpretation.
This chapter shall be so applied and construed as to effectuate its general purpose to make uniform the law with respect to
the subject of this chapter among those states which enact it.
16 Del. C. 1953, § 4775; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4794. Short title.
This chapter may be cited as the Uniform Controlled Substances Act.
16 Del. C. 1953, § 4776; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4795. Jurisdiction.
(a) The Superior Court shall have original and exclusive jurisdiction over any violation of this chapter by persons 18 years
of age or older.
(b) The provisions of subsection (a) of this section or any other law to the contrary notwithstanding, the Court of Common
Pleas shall have original jurisdiction over any violation of:
(1) Section 4754(b) of this title;
(2) Section 4757(c) of this title; and
(3) Section 4771 of this title,
by persons 18 years of age or older, except that the Municipal Court of the City of Wilmington shall have original jurisdiction
concurrent with the Court of Common Pleas for such violations by persons 18 years of age or older occurring within the City
of Wilmington.
(c) The Family Court shall have original and exclusive jurisdiction over violations of this chapter by persons under age 18.
16 Del. C. 1953, § 4777; 58 Del. Laws, c. 424, § 1; 58 Del. Laws, c. 480, § 3; 61 Del. Laws, c. 261, § 4; 62 Del. Laws, c. 250, § 5; 71 Del. Laws, c. 63, §§ 2, 3; 71 Del. Laws, c. 176, § 25.;
§ 4796. Authority of the Attorney General.
Nothing in this chapter shall be interpreted as limiting the authority or responsibility of the Attorney General of this State
to enforce the laws of this State.
16 Del. C. 1953, § 4778; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
(a) Effective October 1, 2010, every prescription written in this State by a practitioner shall be written on a statewide
authorized tamper-resistant prescription form. This section shall not apply to prescriptions generated within a licensed medical
facility that results in the internal dispensing of prescription drugs to any patient receiving treatment in that facility,
nor to tamper-resistant prescription forms electronically generated within a licensed medical facility that meet the criteria
established by the committee created under this section.
(b) "Statewide tamper-resistant prescription pads" shall be defined as a prescription pad, which has been authorized by the
State for use, and meets the following criteria:
(1) Prevention of unauthorized copying,
(2) Prevention of erasure or modification; and
(3) An ability to prevent counterfeit prescription forms.
(c) The Secretary of the Delaware Department of Safety and Homeland Security (DSHS), or the Secretary's designee, shall form
a committee consisting of representatives of state agencies and private sector interests. The purpose of the committee is
to establish a statewide prescription form with specific criteria pursuant to this section to eliminate or significantly reduce
prescription fraud. The committee shall develop the standard format and identifying markers on the front and back of the prescription
form to be used by practitioners throughout the State. "Markers" shall be defined as the specific criteria under this subsection
which shall be authorized by the State to be used on a statewide prescription form. The committee shall further develop a
request for proposal which shall contain the adopted format and criteria approved by the committee to be submitted for bid
to the State. The committee shall also have the authority to promulgate rules and regulations for the implementation of the
provisions of this subsection. The committee shall be comprised of the following members:
(1) The Secretary of the Department of Safety and Homeland Security or the Secretary's designee;
(2) A representative from the Office of Narcotics and Dangerous Drugs to be appointed by the Secretary of the Department of
Safety and Homeland Security;
(3) A representative from the Medical Society of Delaware to be appointed by the Governor;
(4) A representative from the pharmaceutical industry to be appointed by the Governor;
(5) The Director of the Division of Professional Regulation or the Director's designee;
(6) A representative of the Delaware Healthcare Facilities Association to be appointed by the Governor;
(7) The Director of Medicaid and Medical Assistance or the Director's designee;
(8) A representative of the Board of Pharmacy to be appointed by the Director of the Division of Professional Regulation;
(9) A representative from the Delaware Healthcare Association to be appointed by the Governor;
(10) A representative from the Office of Controlled Substances to be appointed by the Director of the Division of Professional
Regulation;
(11) A representative from the Delaware Pharmacists Society to be appointed by the Governor;
(12) Two members at-large to be appointed by the Governor of the State.
76 Del. Laws, c. 352, § 1; 70 Del. Laws, c. 186, § 1; 77 Del. Laws, c. 159, § 1.;
§ 4798. The Delaware Prescription Monitoring Program [Effective upon provision of funding; see 77 Del. Laws, c. 396, § 3]
(a) It is the intent of the General Assembly that the Delaware Prescription Monitoring Act established pursuant to this section
serves as a means to promote public health and welfare and to detect the illegal use of controlled substances. The Delaware
Prescription Monitoring Act shall have the dual purpose of reducing misuse and diversion of controlled substances in the State
while promoting improved professional practice and patient care.
(b) Definitions. --
(1) "Administer" or "administration" means the direct application of a drug to the body of a patient by injection, inhalation,
ingestion, or any other means.
(2) "Controlled substance" means any substance or drug defined, enumerated or included in this chapter and Title 21, Code
of Federal Regulations.
(3) "Dispense" or "dispensing" means the interpretation, evaluation, and implementation of a prescription drug or, including
the preparation and delivery of a drug to a patient or patient's agent in a suitable container appropriately labeled for subsequent
administration to, or use by, a patient.
(4) "Dispenser" means a person authorized by this State to dispense or distribute to the ultimate user any controlled substance
or drug monitored by the program, but shall not include any of the following: a licensed health care facility pharmacy that
dispenses or distributes any controlled substance or drug monitored by the program for the purposes of inpatient care, emergency
department care for the immediate use of a controlled substance or when dispensing up to a 72-hour supply of a controlled
substance or a drug of concern monitored by the program at the time of discharge from such a facility.
(5) "Distribute" or "distribution" means the delivery of a drug other than by administering or dispensing.
(6) "Drug" means any of the following:
a. Any substance recognized as a drug in the official compendium, or supplement thereto, designated by the Office of Controlled
Substances for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans.
b. Any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or pain in humans.
c. Any substance other than food intended to affect the structure or any function of the body of humans.
(7) "Drugs of concern" means drugs other than controlled substances as defined by rule which demonstrate a potential for abuse
or diversion.
(8) "Patient" means the person who is the ultimate user of a controlled substance or drug monitored by the program for whom
a prescription is issued and for whom a controlled substance or drug is dispensed.
(9) "Prescriber" means a licensed health care professional with the authority to write and issue prescriptions, except it
shall not include:
a. A prescriber or other authorized person who administers such controlled substance or drug upon the lawful order of a prescriber.
b. A prescriber or other authorized person who, in providing emergency patient care in a healthcare facility, causes the administration
of a controlled substance for immediate relief of symptoms arising from an acute condition.
c. A prescriber or other authorized person who prescribes up to a 72-hour supply of a controlled substance for on call services
or emergency care.
d. A veterinarian who prescribes for the purpose of providing veterinary services.
(10) "Prescription monitoring information" means data submitted to and maintained by the prescription monitoring program established
under this section.
(11) "Prescription Monitoring Program" or "PMP" means the electronic program established by this section.
(c) The Office of Controlled Substances shall establish and maintain a PMP program to monitor the prescribing and dispensing
of all Schedule II, III, IV and V controlled substances by prescribers in this State, and to research the prescribing and
dispensing of drugs of concern. The PMP shall not interfere with the legal use of a controlled substance or drug of concern.
The PMP shall be:
(1) Used to provide information to prescribers, dispensers, and patients to help avoid the illegal use of controlled substances;
(2) Used to assist law enforcement to investigate illegal activity related to the prescribing, dispensing and consumption
of controlled substances or drugs of concern; and
(3) Designed to minimize inconvenience to patients and prescribing medical practitioners while effectuating the collection
and storage of prescription monitoring information.
(d) A dispenser shall submit the required information regarding each prescription dispensed for a controlled substance, in
accordance with the transmission methods and frequency established by regulation issued by the Office of Controlled Substances.
When needed for bona fide research purposes and in accordance with applicable regulation, the Office of Controlled Substances
may require a dispenser to submit the required information regarding each prescription dispensed for a drug of concern, but
in no event should dispensers be required to submit such information any more frequently than that required for controlled
substances. The following information shall be submitted for each prescription:
(1) Pharmacy name;
(2) Dispenser DEA registration number;
(3) Date drug was dispensed;
(4) Prescription number;
(5) Whether prescription is new or a refill;
(6) NDC code for drug dispensed;
(7) Quantity dispensed;
(8) Approximate number of days supplied;
(9) Patient name and date of birth;
(10) Patient address;
(11) Prescriber DEA registration number and name;
(12) Date prescription issued by prescriber.
(e) A prescriber, or other person authorized by the prescriber, shall obtain, before writing a prescription for a controlled
substance listed in Schedule II, III, IV or V for a patient, a patient utilization report regarding the patient for the preceding
12 months from the computerized program established by the Office of Controlled Substances when the prescriber has a reasonable
belief that the patient may be seeking the controlled substance, in whole or in part, for any reason other than the treatment
of an existing medical condition. The prescriber shall review the patient utilization report to assess whether the prescription
for the controlled substance is necessary.
(f) The Office of Controlled Substances may issue a waiver to a prescriber who is unable to access prescription information
by electronic means. A prescriber who is unable to access prescription information by electronic means shall obtain a waiver
from the OCS on annual basis until such time they can access the prescription information by electronic means.
(g) Unless a court of competent jurisdiction makes a finding of gross negligence, malice or criminal intent, the Office of
Controlled Substances, any other state agency, any prescriber or dispenser, or any person or entity in proper possession of
information pursuant to this statute is not subject to civil liability, administrative action or other legal or equitable
relief for any of the following acts or omissions:
(1) Furnishing information pursuant to this section.
(2) Receiving, using or relying on, or not using or relying on, information received pursuant to this section.
(3) Information that was not furnished to the Office of Controlled Substances.
(4) Information that was factually incorrect or that was released by the Office of Controlled Substance to the wrong person
or entity.
(h) Prescription information submitted to the PMP is protected health information, not subject to public or open records law,
and not subject to disclosure, except as otherwise provided in this section.
(i) The Office of Controlled Substances shall maintain procedures to ensure that the privacy and confidentiality of patients
and patient information collected, recorded, transmitted, and maintained is not disclosed, except as provided for in this
section.
(1) If there is reasonable cause to believe a violation of law or breach of professional standards may have occurred, the
Office of Controlled Substances shall notify the appropriate law-enforcement or professional licensure, certification, or
regulatory agency or entity and shall provide prescription information required for an investigation.
(2) The Office of Controlled Substances may provide data in the prescription monitoring program in the form of a report to
the following persons:
a. A prescriber, or other person authorized by the prescriber, or a dispenser, or other person authorized by the dispenser,
who requests information and certifies that the requested information is for the purpose of providing medical or pharmaceutical
treatment to a bona fide patient;
b. An individual who requests the individual's own prescription monitoring information in accordance with procedures established
pursuant to regulations;
c. A designated representative of any Board or Commission pursuant to § 8735(a) of Title 29 responsible for the licensure,
regulation, or discipline of prescribers, dispensers or other persons authorized to prescribe, administer, or dispense controlled
substances and who is involved in a bona fide specific investigation involving a designated person;
d. A local, state, or federal law-enforcement or prosecutorial official engaged in the administration, investigation, or enforcement
of the laws governing controlled substances and who is involved in a bona fide specific drug-related investigation in which
a report of suspected criminal activity involving controlled substances by an identified suspect has been made, and provided
that such information be relevant and material to such investigation, limited in scope to the extent reasonably practicable
in light of the purpose for which the information is sought, and include identifying information only if nonidentifying information
could not be used;
e. The Delaware Department of Health and Social Services regarding Medicaid program recipients;
f. A properly convened grand jury pursuant to a subpoena properly issued for the records;
g. Personnel of the Division of Professional Regulation for purposes of administration and enforcement of this section;
h. Qualified personnel for the purpose of bona fide research or education; however, data elements that would reasonably identify
a specific recipient, prescriber or dispenser must be deleted or redacted from such information prior to disclosure; and further
provided that, release of the information may be made only pursuant to a written agreement between qualified personnel and
the Office of Controlled Substances in order to ensure compliance with this subsection.
(j) The Division of Professional Regulation may contract with another agency of this State or with a private vendor, as necessary,
to ensure the effective operation of the prescription monitoring program. A contractor shall comply with the provisions regarding
confidentiality of prescription information under this section is subject to the penalties specified in this section for any
unlawful acts.
(k) The Office of Controlled Substances may promulgate regulations setting forth the procedures and methods for implementing
this section.
(l) The Office of Controlled Substances shall design and implement an evaluation component to identify cost-benefits of the
Prescription Monitoring Program, including its effect on diversion and abuse of controlled substances and drugs of concern,
and other information relevant to policy, research and education involving controlled substances and drugs of concern monitored
by the Prescription Monitoring Program.
(1) The Office of Controlled Substances shall report to the General Assembly the information obtained pursuant to this subsection
on an annual basis.
(2) To the extent such information is made available to the Office of Controlled Substances, the report may include information
and data, including surveys, polls, or other data from multi-disciplinary experts and stakeholders, relating to the negative
or positive impact of the prescription monitoring program on appropriate prescribing practices of controlled substances and
drugs of concern.
(m) A dispenser who fails to submit prescription monitoring information to the Office of Controlled Substances PMP as required
by this section, or who knowingly submits incorrect prescription information, shall be subject to disciplinary sanction pursuant
to Chapter 25 of Title 24.
(n) A person or persons authorized to have prescription monitoring information pursuant to this section who knowingly discloses
this information in violation of this section is guilty of a class G felony and, upon conviction, shall be fined not more
than $5,000 nor imprisoned more than 2 years, or both.
(o) A person authorized to have prescription monitoring information pursuant to this section who intentionally uses this information
in the furtherance of other crimes is guilty of a class E felony and, upon conviction, shall be fined not more than $10,000
nor imprisoned more than 5 years, or both.
(p) A person or persons not authorized to have prescription monitoring information pursuant to this section who obtain such
information fraudulently is guilty of a class E felony and, upon conviction, shall be fined not more than $10,000 nor imprisoned
more than 5 years, or both.
(a) Prosecution for any violation of law occurring prior to the effective date of this chapter is not affected or abated by
this chapter. If the offense being prosecuted is similar to one set out in subchapter IV of this chapter, then the penalties
under subchapter IV apply if they are less than those under prior law.
(b) Civil seizures or forfeitures and injunctive proceedings commenced prior to the effective date of this chapter are not
affected by this chapter.
(c) All administrative proceedings pending under prior laws which are superseded by this chapter shall be continued and brought
to a final determination in accord with the laws or rules in effect prior to the effective date of the chapter. Any substance
controlled under prior law which is not listed within Schedules I through V is automatically controlled without further proceedings
and shall be listed in the appropriate schedule.
(d) The Secretary shall initially permit persons to register who own or operate any establishment engaged in the manufacture,
distribution or dispensing of any controlled substance prior to the effective date of this chapter and who are registered
or licensed by the State.
(e) This chapter applies to violations of law, seizures and forfeiture, injunctive proceedings, administrative proceedings
and investigations which occur following its effective date.
16 Del. C. 1953, § 4773; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4792. Continuation of rules.
Any orders and rules promulgated under any law affected by this chapter and in effect on the effective date of this chapter
and not in conflict with it continue in effect until modified, superseded or repealed.
16 Del. C. 1953, § 4774; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4793. Uniformity of interpretation.
This chapter shall be so applied and construed as to effectuate its general purpose to make uniform the law with respect to
the subject of this chapter among those states which enact it.
16 Del. C. 1953, § 4775; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4794. Short title.
This chapter may be cited as the Uniform Controlled Substances Act.
16 Del. C. 1953, § 4776; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
§ 4795. Jurisdiction.
(a) The Superior Court shall have original and exclusive jurisdiction over any violation of this chapter by persons 18 years
of age or older.
(b) The provisions of subsection (a) of this section or any other law to the contrary notwithstanding, the Court of Common
Pleas shall have original jurisdiction over any violation of:
(1) Section 4754(b) of this title;
(2) Section 4757(c) of this title; and
(3) Section 4771 of this title,
by persons 18 years of age or older, except that the Municipal Court of the City of Wilmington shall have original jurisdiction
concurrent with the Court of Common Pleas for such violations by persons 18 years of age or older occurring within the City
of Wilmington.
(c) The Family Court shall have original and exclusive jurisdiction over violations of this chapter by persons under age 18.
16 Del. C. 1953, § 4777; 58 Del. Laws, c. 424, § 1; 58 Del. Laws, c. 480, § 3; 61 Del. Laws, c. 261, § 4; 62 Del. Laws, c. 250, § 5; 71 Del. Laws, c. 63, §§ 2, 3; 71 Del. Laws, c. 176, § 25.;
§ 4796. Authority of the Attorney General.
Nothing in this chapter shall be interpreted as limiting the authority or responsibility of the Attorney General of this State
to enforce the laws of this State.
16 Del. C. 1953, § 4778; 58 Del. Laws, c. 424, § 1; 62 Del. Laws, c. 250, § 5.;
(a) Effective October 1, 2010, every prescription written in this State by a practitioner shall be written on a statewide
authorized tamper-resistant prescription form. This section shall not apply to prescriptions generated within a licensed medical
facility that results in the internal dispensing of prescription drugs to any patient receiving treatment in that facility,
nor to tamper-resistant prescription forms electronically generated within a licensed medical facility that meet the criteria
established by the committee created under this section.
(b) "Statewide tamper-resistant prescription pads" shall be defined as a prescription pad, which has been authorized by the
State for use, and meets the following criteria:
(1) Prevention of unauthorized copying,
(2) Prevention of erasure or modification; and
(3) An ability to prevent counterfeit prescription forms.
(c) The Secretary of the Delaware Department of Safety and Homeland Security (DSHS), or the Secretary's designee, shall form
a committee consisting of representatives of state agencies and private sector interests. The purpose of the committee is
to establish a statewide prescription form with specific criteria pursuant to this section to eliminate or significantly reduce
prescription fraud. The committee shall develop the standard format and identifying markers on the front and back of the prescription
form to be used by practitioners throughout the State. "Markers" shall be defined as the specific criteria under this subsection
which shall be authorized by the State to be used on a statewide prescription form. The committee shall further develop a
request for proposal which shall contain the adopted format and criteria approved by the committee to be submitted for bid
to the State. The committee shall also have the authority to promulgate rules and regulations for the implementation of the
provisions of this subsection. The committee shall be comprised of the following members:
(1) The Secretary of the Department of Safety and Homeland Security or the Secretary's designee;
(2) A representative from the Office of Narcotics and Dangerous Drugs to be appointed by the Secretary of the Department of
Safety and Homeland Security;
(3) A representative from the Medical Society of Delaware to be appointed by the Governor;
(4) A representative from the pharmaceutical industry to be appointed by the Governor;
(5) The Director of the Division of Professional Regulation or the Director's designee;
(6) A representative of the Delaware Healthcare Facilities Association to be appointed by the Governor;
(7) The Director of Medicaid and Medical Assistance or the Director's designee;
(8) A representative of the Board of Pharmacy to be appointed by the Director of the Division of Professional Regulation;
(9) A representative from the Delaware Healthcare Association to be appointed by the Governor;
(10) A representative from the Office of Controlled Substances to be appointed by the Director of the Division of Professional
Regulation;
(11) A representative from the Delaware Pharmacists Society to be appointed by the Governor;
(12) Two members at-large to be appointed by the Governor of the State.
76 Del. Laws, c. 352, § 1; 70 Del. Laws, c. 186, § 1; 77 Del. Laws, c. 159, § 1.;
§ 4798. The Delaware Prescription Monitoring Program [Effective upon provision of funding; see 77 Del. Laws, c. 396, § 3]
(a) It is the intent of the General Assembly that the Delaware Prescription Monitoring Act established pursuant to this section
serves as a means to promote public health and welfare and to detect the illegal use of controlled substances. The Delaware
Prescription Monitoring Act shall have the dual purpose of reducing misuse and diversion of controlled substances in the State
while promoting improved professional practice and patient care.
(b) Definitions. --
(1) "Administer" or "administration" means the direct application of a drug to the body of a patient by injection, inhalation,
ingestion, or any other means.
(2) "Controlled substance" means any substance or drug defined, enumerated or included in this chapter and Title 21, Code
of Federal Regulations.
(3) "Dispense" or "dispensing" means the interpretation, evaluation, and implementation of a prescription drug or, including
the preparation and delivery of a drug to a patient or patient's agent in a suitable container appropriately labeled for subsequent
administration to, or use by, a patient.
(4) "Dispenser" means a person authorized by this State to dispense or distribute to the ultimate user any controlled substance
or drug monitored by the program, but shall not include any of the following: a licensed health care facility pharmacy that
dispenses or distributes any controlled substance or drug monitored by the program for the purposes of inpatient care, emergency
department care for the immediate use of a controlled substance or when dispensing up to a 72-hour supply of a controlled
substance or a drug of concern monitored by the program at the time of discharge from such a facility.
(5) "Distribute" or "distribution" means the delivery of a drug other than by administering or dispensing.
(6) "Drug" means any of the following:
a. Any substance recognized as a drug in the official compendium, or supplement thereto, designated by the Office of Controlled
Substances for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans.
b. Any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or pain in humans.
c. Any substance other than food intended to affect the structure or any function of the body of humans.
(7) "Drugs of concern" means drugs other than controlled substances as defined by rule which demonstrate a potential for abuse
or diversion.
(8) "Patient" means the person who is the ultimate user of a controlled substance or drug monitored by the program for whom
a prescription is issued and for whom a controlled substance or drug is dispensed.
(9) "Prescriber" means a licensed health care professional with the authority to write and issue prescriptions, except it
shall not include:
a. A prescriber or other authorized person who administers such controlled substance or drug upon the lawful order of a prescriber.
b. A prescriber or other authorized person who, in providing emergency patient care in a healthcare facility, causes the administration
of a controlled substance for immediate relief of symptoms arising from an acute condition.
c. A prescriber or other authorized person who prescribes up to a 72-hour supply of a controlled substance for on call services
or emergency care.
d. A veterinarian who prescribes for the purpose of providing veterinary services.
(10) "Prescription monitoring information" means data submitted to and maintained by the prescription monitoring program established
under this section.
(11) "Prescription Monitoring Program" or "PMP" means the electronic program established by this section.
(c) The Office of Controlled Substances shall establish and maintain a PMP program to monitor the prescribing and dispensing
of all Schedule II, III, IV and V controlled substances by prescribers in this State, and to research the prescribing and
dispensing of drugs of concern. The PMP shall not interfere with the legal use of a controlled substance or drug of concern.
The PMP shall be:
(1) Used to provide information to prescribers, dispensers, and patients to help avoid the illegal use of controlled substances;
(2) Used to assist law enforcement to investigate illegal activity related to the prescribing, dispensing and consumption
of controlled substances or drugs of concern; and
(3) Designed to minimize inconvenience to patients and prescribing medical practitioners while effectuating the collection
and storage of prescription monitoring information.
(d) A dispenser shall submit the required information regarding each prescription dispensed for a controlled substance, in
accordance with the transmission methods and frequency established by regulation issued by the Office of Controlled Substances.
When needed for bona fide research purposes and in accordance with applicable regulation, the Office of Controlled Substances
may require a dispenser to submit the required information regarding each prescription dispensed for a drug of concern, but
in no event should dispensers be required to submit such information any more frequently than that required for controlled
substances. The following information shall be submitted for each prescription:
(1) Pharmacy name;
(2) Dispenser DEA registration number;
(3) Date drug was dispensed;
(4) Prescription number;
(5) Whether prescription is new or a refill;
(6) NDC code for drug dispensed;
(7) Quantity dispensed;
(8) Approximate number of days supplied;
(9) Patient name and date of birth;
(10) Patient address;
(11) Prescriber DEA registration number and name;
(12) Date prescription issued by prescriber.
(e) A prescriber, or other person authorized by the prescriber, shall obtain, before writing a prescription for a controlled
substance listed in Schedule II, III, IV or V for a patient, a patient utilization report regarding the patient for the preceding
12 months from the computerized program established by the Office of Controlled Substances when the prescriber has a reasonable
belief that the patient may be seeking the controlled substance, in whole or in part, for any reason other than the treatment
of an existing medical condition. The prescriber shall review the patient utilization report to assess whether the prescription
for the controlled substance is necessary.
(f) The Office of Controlled Substances may issue a waiver to a prescriber who is unable to access prescription information
by electronic means. A prescriber who is unable to access prescription information by electronic means shall obtain a waiver
from the OCS on annual basis until such time they can access the prescription information by electronic means.
(g) Unless a court of competent jurisdiction makes a finding of gross negligence, malice or criminal intent, the Office of
Controlled Substances, any other state agency, any prescriber or dispenser, or any person or entity in proper possession of
information pursuant to this statute is not subject to civil liability, administrative action or other legal or equitable
relief for any of the following acts or omissions:
(1) Furnishing information pursuant to this section.
(2) Receiving, using or relying on, or not using or relying on, information received pursuant to this section.
(3) Information that was not furnished to the Office of Controlled Substances.
(4) Information that was factually incorrect or that was released by the Office of Controlled Substance to the wrong person
or entity.
(h) Prescription information submitted to the PMP is protected health information, not subject to public or open records law,
and not subject to disclosure, except as otherwise provided in this section.
(i) The Office of Controlled Substances shall maintain procedures to ensure that the privacy and confidentiality of patients
and patient information collected, recorded, transmitted, and maintained is not disclosed, except as provided for in this
section.
(1) If there is reasonable cause to believe a violation of law or breach of professional standards may have occurred, the
Office of Controlled Substances shall notify the appropriate law-enforcement or professional licensure, certification, or
regulatory agency or entity and shall provide prescription information required for an investigation.
(2) The Office of Controlled Substances may provide data in the prescription monitoring program in the form of a report to
the following persons:
a. A prescriber, or other person authorized by the prescriber, or a dispenser, or other person authorized by the dispenser,
who requests information and certifies that the requested information is for the purpose of providing medical or pharmaceutical
treatment to a bona fide patient;
b. An individual who requests the individual's own prescription monitoring information in accordance with procedures established
pursuant to regulations;
c. A designated representative of any Board or Commission pursuant to § 8735(a) of Title 29 responsible for the licensure,
regulation, or discipline of prescribers, dispensers or other persons authorized to prescribe, administer, or dispense controlled
substances and who is involved in a bona fide specific investigation involving a designated person;
d. A local, state, or federal law-enforcement or prosecutorial official engaged in the administration, investigation, or enforcement
of the laws governing controlled substances and who is involved in a bona fide specific drug-related investigation in which
a report of suspected criminal activity involving controlled substances by an identified suspect has been made, and provided
that such information be relevant and material to such investigation, limited in scope to the extent reasonably practicable
in light of the purpose for which the information is sought, and include identifying information only if nonidentifying information
could not be used;
e. The Delaware Department of Health and Social Services regarding Medicaid program recipients;
f. A properly convened grand jury pursuant to a subpoena properly issued for the records;
g. Personnel of the Division of Professional Regulation for purposes of administration and enforcement of this section;
h. Qualified personnel for the purpose of bona fide research or education; however, data elements that would reasonably identify
a specific recipient, prescriber or dispenser must be deleted or redacted from such information prior to disclosure; and further
provided that, release of the information may be made only pursuant to a written agreement between qualified personnel and
the Office of Controlled Substances in order to ensure compliance with this subsection.
(j) The Division of Professional Regulation may contract with another agency of this State or with a private vendor, as necessary,
to ensure the effective operation of the prescription monitoring program. A contractor shall comply with the provisions regarding
confidentiality of prescription information under this section is subject to the penalties specified in this section for any
unlawful acts.
(k) The Office of Controlled Substances may promulgate regulations setting forth the procedures and methods for implementing
this section.
(l) The Office of Controlled Substances shall design and implement an evaluation component to identify cost-benefits of the
Prescription Monitoring Program, including its effect on diversion and abuse of controlled substances and drugs of concern,
and other information relevant to policy, research and education involving controlled substances and drugs of concern monitored
by the Prescription Monitoring Program.
(1) The Office of Controlled Substances shall report to the General Assembly the information obtained pursuant to this subsection
on an annual basis.
(2) To the extent such information is made available to the Office of Controlled Substances, the report may include information
and data, including surveys, polls, or other data from multi-disciplinary experts and stakeholders, relating to the negative
or positive impact of the prescription monitoring program on appropriate prescribing practices of controlled substances and
drugs of concern.
(m) A dispenser who fails to submit prescription monitoring information to the Office of Controlled Substances PMP as required
by this section, or who knowingly submits incorrect prescription information, shall be subject to disciplinary sanction pursuant
to Chapter 25 of Title 24.
(n) A person or persons authorized to have prescription monitoring information pursuant to this section who knowingly discloses
this information in violation of this section is guilty of a class G felony and, upon conviction, shall be fined not more
than $5,000 nor imprisoned more than 2 years, or both.
(o) A person authorized to have prescription monitoring information pursuant to this section who intentionally uses this information
in the furtherance of other crimes is guilty of a class E felony and, upon conviction, shall be fined not more than $10,000
nor imprisoned more than 5 years, or both.
(p) A person or persons not authorized to have prescription monitoring information pursuant to this section who obtain such
information fraudulently is guilty of a class E felony and, upon conviction, shall be fined not more than $10,000 nor imprisoned
more than 5 years, or both.
